Contact information
Type
Scientific
Primary contact
Dr Matthew Walters
ORCID ID
Contact details
Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom
+44 (0)141 211 2821
gcl203@clinmed.gla.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol
Acronym
Study hypothesis
To investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension.
Ethics approval
West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1)
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Treatment
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Condition
Hypertension
Intervention
Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet.
Intervention type
Drug
Phase
Not Applicable
Drug names
Losartan, atenolol
Primary outcome measures
Changes in cerebrovascular reactivity.
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/08/2004
Overall trial end date
01/02/2006
Reason abandoned
Eligibility
Participant inclusion criteria
1. Male: 50-80 years
2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH)
3. Blood pressure (BP) 150-200/90-115
Participant type
Patient
Age group
Adult
Gender
Male
Target number of participants
13
Participant exclusion criteria
1. >70% internal carotid artery (ICA) stenosis
2. Middle cerebral artery (MCA) stenosis
3. Contra-indication to losartan, atenolol or acetazolamide
4. Serum creatinine >130 µmol/l
5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment
Recruitment start date
01/08/2004
Recruitment end date
01/02/2006
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Western Infirmary
Glasgow
G11 6NT
United Kingdom
Sponsor information
Organisation
University of Glasgow (UK)
Sponsor details
University Avenue
Glasgow
G11 6NT
United Kingdom
+44 (0)141 211 2176
pcn1w@clinmed.gla.ac.uk
Sponsor type
University/education
Website
Funders
Funder type
University/education
Funder name
University of Glasgow
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
academic
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary